Join to view full profile
201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194
Dr. Le is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dung Le, MD, is an oncologist based in Baltimore, MD, with a subspecialty in Hematologic Oncology. She completed her education and training at the prestigious Johns Hopkins University School of Medicine, where she also completed a fellowship in Hematology and Medical Oncology. Dr. Le has extensive experience in gastrointestinal oncology and general medical oncology, with several publications in reputable journals including the Journal for Immunotherapy of Cancer and Clinical Cancer Research. She is currently involved in multiple clinical trials focusing on advanced solid tumors and pancreatic cancer. In 2013-2014, Dr. Le received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007- Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
- Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
MD State Medical License 2004 - 2028
PA State Medical License 2024 - 2026
NH State Medical License 2024 - 2024
WI State Medical License 2022 - 2023
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
OK State Medical License 2021 - 2021
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
- QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
- Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Start of enrollment: 2011 Sep 21
Publications & Presentations
PubMed
- Outcomes of Patients with ≥ 8mm Indeterminate Pulmonary Nodules at the Time of Liver Resection for Metastatic Colorectal Cancer.H Catherine Wilbur, Heng-Chung Kung, Reena Suresh, Thanh Nguyen, Javad Azadi
Journal of Gastrointestinal Surgery. 2026-09-17 - Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.Eric S Christenson, Jeremiah A Wala, Rose Parkinson, Natalie B Collins, Christopher Jakubowski
Nature Communications. 2026-07-23 - 1 citationsMutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.Hejia Henry Wang, Amanda L Huff, S Daniel Haldar, Maureen Berg, Christopher Thoburn
Nature Communications. 2026-06-23
Press Mentions
Immunotherapy for Colon CancerSeptember 4th, 2019
Tumor Gene Testing Urged to Tell if Drug Targets Your CancerJuly 6th, 2017
Nivolumab Improves OS in Phase III Gastric Cancer StudyNovember 10th, 2016
Other Languages
- Vietnamese
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/dung-le
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
